Trial intelligence / Profile preview

Phase 2 open-label neratinib study in ERBB-mutant or EGFR-amplified solid tumors

2013-002872-42Phase 2Completed

Sponsor

Puma Biotechnology, Inc.

Start

Jan 2014

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1